Håvard Midgard

[Håvard Midgard @HMidgard]

@DrToddLee @AnilMakam @PaulSaxMD @zchagla @selihep Renal AA amyloiosis probably most frequent cause of renal failure among PWID in Oslo.

[Håvard Midgard @HMidgard]

@DrToddLee @AnilMakam @PaulSaxMD @zchagla @selihep This was a pragmatic trial mirroring real-world settings but I think we were pretty sober. Most patients with short life expectancy (eg end stage renal disease and not dialysis candidates) were left untreated.

[Håvard Midgard @HMidgard]

@AnilMakam @PaulSaxMD @zchagla @selihep Of note, Norway has achieved substantial DAA price reductions in recent years - approx USD 2600 for 8wks Zepatier for instance. The DAA costs are covered by the regional health authorities.

[Håvard Midgard @HMidgard]

@AnilMakam @PaulSaxMD @zchagla @selihep Study participants reflected an ageing HCV-population in a period where Norway was approaching HCV elimination. A total of 7.5% were not treated due to short life expectancy and most of those who died remained untreated for the same reason.

[drklausner @drklausner]

What a concept! Starting treatment for people with chronic but curable infections in the hospital. Too bad most insurers and @MedicareGov won’t cover such out-patient issues.

[Shashi Kapadia @ShashiKapadiaMD]

Inspiring work by inspiring people @Ane_Kristine @HMidgard @selihep - It's time to stop writing "hcv, defer to outpatient" in your consult notes, #idtwitter

[Clinical Infectious Diseases @CIDJournal]

Opportunistic treatment of hepatitis C infection among hospitalized people who inject drugs (OPPORTUNI-C): A stepped wedge cluster randomized trial

✅ Just Accepted
🔓 Open Access
🔗 https://t.co/59TaFsHeXP

via @HMidgard @selihep

[Paul Sax @PaulSaxMD]

Remarkable RCT from Norway demonstrating that starting HCV treatment in the hospital with newly diagnosed HCV among PWIDs is superior to deferring therapy to outpatient care in achieving HCV cure.

Results argue for broader use. @HMidgard @selihep https://t.co/BspdLy5hGR

[Clinical Infectious Diseases @CIDJournal]

Don’t put off until tomorrow what you can do today: Hospital admissions as an opportunity to treat hepatitis C

✅ Just Accepted
💬 Editorial Commentary
🔗 https://t.co/5rPPdgzliq

[Håvard Midgard @HMidgard]

Opportunistic treatment of hepatitis C infection among hospitalized people who inject drugs (OPPORTUNI-C): A stepped wedge cluster randomized trial https://t.co/2ocGUjVJ4S

[SELIHEP @selihep]

Last session @INHepSU and grateful that the main result from Opportuni-C was highlighted in @tdbrothers rapporteur! @HMidgard

[SELIHEP @selihep]

Take home message from Kristian Malme today @INHepSU: Although HCV treatment uptake increased among people who inject drugs in 🇳🇴, strategies to improve treatment among women and individuals not engaged in OAT should be addressed!

[INHSU @INHepSU]

Practice changing findings ALERT: from OPPORTUNI-C in Norway, a pragmatic RCT showing inpatient initiation of HCV rx is doable, safe, and WORKS...even in a pandemic. A tour de force from @HMidgard @Ane_Kristine @selihep at #INHSU2022

[SELIHEP @selihep]

At #INHSU2021 session #Innovations in HepC Testing and Treatment @HMidgard presented live #peer #mobile #HCVclinic.

[Anne Oevrehus @Oevrehusdk]

@HMidgard How can we achieve WHO's elimination target for hepatitis C incidence? https://t.co/6zfT3GkOWs

[Anne Oevrehus @Oevrehusdk]

Big shout out to @HMidgard and colleagues from Oslo on their work to reach people with recent injecting drug use at #ILC2019 - Treatment uptske 65% so far half of untested LTFU @Cfritsyd

[Gottfried Hirnschall @GHirnschall]

We @WHO just released a new report on #hepatitis C treatment. It shows the annual number of people initiating HCV curative treatment increased from 1 mln in 2015 to 1.5 mln in 2016. But access is focused primarily in a few high-burden countries. https://t.co/V6q8eqgvRh #NOHEP

[Journal of Hepatology @JHepatology]

«The times they are a’changin’» – Positioning @EASLnews in the changing landscape of hepatology

https://t.co/6cWe3Hkk2u
@tomhemmingk

[EASL Education @EASLedu]

#EASLmono conf on elimination of #hepatitisC infection was a great success, watch the webcasts & ePosters on #EASL #LiverTree
https://t.co/FFr4GfygCL #HCV #publichealth #testing #treatment #epidemiology @EASLnews @JVLazarus @JMPawlotsky @aelsharkawy75 @AghemoAlessio

[Anne Oevrehus @Oevrehusdk]

He did a great job. Thank you @jasongrebely @martinkaberg for the video greetings. His work will be the foundations for NO #hepc strategy https://t.co/HFsfb95mBw